ArticleHLA2025
HLA-B Leader Dimorphism Predicts BK Polyomavirus Replication After Kidney Transplant.
Article in HLA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK polyomavirus (BKPyV) and Cytomegalovirus (CMV) often replicate after kidney transplantation, with management limited to reducing immunosuppression and risking rejection. Among genetic factors that may modulate the antiviral response, HLA evolutionary divergence (HED, allowing a greater diversity of antigen presentation) and the HLA-B leader dimorphism (MM, MT, TT, influencing NK cell-mediated immunity) are interesting. We aimed to compare these parameters between patients who experienced viral replication within the first post-transplant year and those who did not. We analysed 306 kidney transplants performed between 2019 and 2023 at Amiens University Hospital. HLA typing was performed in recipients and donors to determine HED (loci A, B, C, DRB1, DQB1) and HLA-B leader dimorphism. 22.5% of the recipients (69/306) developed BKPyV possible nephropathy (defined by urinary PCR > 7 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.